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Abstract
Purpose Triacetone triperoxide (TATP) is a volatile but powerful explosive that appeals to terrorists due to its ease of synthesis from household items. For this reason, bomb squad, canine (K9) units, and scientists must work with this material to
mitigate this threat. However, no information on the metabolism of TATP is available.
Methods In vitro experiments using human liver microsomes and recombinant enzymes were performed on TATP and TATPOH for metabolite identification and enzyme phenotyping. Enzyme kinetics for TATP hydroxylation were also investigated.
Urine from laboratory personnel collected before and after working with TATP was analyzed for TATP and its metabolites.
Results While experiments with flavin monooxygenases were inconclusive, those with recombinant cytochrome P450s
(CYPs) strongly suggested that CYP2B6 was the principle enzyme responsible for TATP hydroxylation. TATP-O-glucuronide
was also identified and incubations with recombinant uridine diphosphoglucuronosyltransferases (UGTs) indicated that
UGT2B7 catalyzes this reaction. Michaelis–Menten kinetics were determined for TATP hydroxylation, with Km = 1.4 µM
and Vmax = 8.7 nmol/min/nmol CYP2B6. TATP-O-glucuronide was present in the urine of all three volunteers after being
exposed to TATP vapors showing good in vivo correlation to in vitro data. TATP and TATP-OH were not observed.
Conclusions Since scientists working to characterize and detect TATP to prevent terrorist attacks are constantly exposed
to this volatile compound, attention should be paid to its metabolism. This paper is the first to elucidate some exposure,
metabolism and excretion of TATP in humans and to identify a marker of TATP exposure, TATP-O-glucuronide in urine.
Keywords Triacetone triperoxide (TATP) · Terrorists · Human in vitro and in vivo metabolism for TATP exposure · TATPO-glucuronide · CYP2B6 hydroxylation · UGT2B7 glucuronidation

Introduction
Triacetone triperoxide (3,3,6,6,9,9-hexamethyl-1,2,4,5,7,8hexoxonane, TATP) is a homemade explosive, easily synthesized from household items [1]. For this reason, TATP has
often been used by terrorists [2, 3], necessitating its research
by bomb squad, canine (K9) units, and scientists [4]. In addition to being extremely hazardous, this peroxide explosive
is highly volatile, with partial pressure of 4–7 Pa at 20 ℃
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[5, 6]. Personnel exposed to TATP will most likely absorb it
through inhalation and/or dermal absorption. However, no
information on the human absorption, distribution, metabolism, excretion and toxicity (ADMET) of TATP is available.
Therefore, this paper will investigate the in vitro metabolism
of TATP and the in vivo excretion through urine analysis.
The toxicity of most military explosives has been well
characterized [7]. The biotransformation of trinitrotoluene,
for example, has been thoroughly investigated. It is metabolized by cytochrome P450 (CYP) reductase, forming nitroso
intermediates, and yielding 4-hydroxylamino-2,6-dinitrotoluene, 4-amino-2,6-dinitrotoluene and 2-amino-4,6-dinitrotoluene. These primary metabolites are further reduced by
CYP to 2,4-diamino-6-nitrotoluene and 2,6-diamino-4-nitrotoluene [8, 9]. In vivo studies of Chinese ammunition factory
workers found metabolites, such as 4-amino-2,6-dinitrotoluene and 2-amino-4,6-dinitrotoluene, in urine and bound
to the hemoglobin in blood [9, 10]. TATP has been studied
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for almost two decades, but its metabolism and toxicity are
still unknown. TATP characterization is problematic since
it is an extremely sensitive explosive, difficult to handle and,
due to its high volatility, difficult to concentrate in biological
samples [5].
Most xenobiotics are metabolized by CYP which is a family of heme-containing enzymes found in all tissues, particularly the liver endoplasmic reticulum (microsomes). CYPs
catalyze phase I oxidative reactions (among others) in the
presence of oxygen and a reducing agent (usually reduced
nicotinamide adenine dinucleotide phosphate, NADPH).
NADPH provides electrons to the CYP heme via CYP
reductase. This oxidation generally produces more polar
metabolites that are either excreted in the urine or undergo
phase II biotransformation, further increasing their hydrophilicity [11]. One of the most common phase II reactions
is glucuronidation, which is catalyzed by uridine diphosphoglucuronosyltransferase (UGT) in the presence of the
cofactor uridine diphosphoglucuronic acid (UDPGA). In this
reaction, glucuronic acid is conjugated onto an electron-rich
nucleophilic heteroatom, frequently added to the substrate
by phase I metabolism. Glucuronide metabolites increase
the topological polar surface area (TPSA) and reduce the
partition coefficient (LogP) of xenobiotics to be ionized at
physiological pH, thus, increasing the aqueous solubility of
the compound for excretion [11].
TATP is a cyclic peroxide, a motif shared with the antimalarial drug, artemisinin. The endoperoxide functionality of
artemisinin is thought to be crucial for its antimalarial activity [12]. In the presence of ferrous ions, artemisinin undergoes homolytic peroxide cleavage to yield an oxygen radical
that may be lethal to malaria parasite, Plasmodium falciparum. Biotransformation studies indicate that artemisinin
is primarily metabolized by CYP2B6 to deoxyartemisinin,
deoxydihydroartemisinin, dihydroartemisinin and ‘crystal-7’
[13, 14]. Similarly, we have previously shown that TATP is
metabolized in vitro by canine CYP2B11, another CYP2B
subfamily enzyme [15]. Artemisinin is further metabolized
by glucuronidation, particularly by UGT1A9 and UGT2B7,
to dihydroartemisinin-glucuronide, the principal metabolite
found in urine, suggesting endoperoxides, like TATP, may
be glucuronidated and excreted in urine [16].
Laboratory personnel who work on synthesizing, characterizing and detecting TATP are inevitably exposed to
this volatile compound. Even the small-sized samples that
they work with can result in buildup of TATP in a confined
space. Furthermore, bomb-sniffing dogs and their handlers
are purposely exposed to these vapors for the sake of training. Our previous study revealed TATP metabolism in dog
liver microsomes (DLM) [15]. Now we evaluate its in vitro
biotransformation in human liver microsomes (HLM) and
recombinant enzymes, identifying phase I and phase II
metabolites, estimating enzyme kinetics and also detecting
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urinary in vivo metabolites excreted from scientists exposed
to TATP in their work environment.

Materials and methods
Chemicals
Optima HPLC grade methanol, Optima HPLC grade water,
Optima HPLC grade acetonitrile, American Chemical Society (ACS) grade acetone, ACS grade methanol, ACS grade
pentane, hydrochloric acid, ammonium acetate, dipotassium phosphate, monopotassium phosphate, magnesium
chloride (MgCl2) and reduced glutathione (GSH) were
purchased from Fisher Chemical (Fair Lawn, NJ, USA);
NADPH, 1-aminobenzotriazole, methimazole, 1-naphthol
and hydroxyacetone from Acros Organics (Morris Plain,
NJ, USA); UDPGA, saccharolactone and 2,4-dichlorophenoxyacetic acid from Sigma-Aldrich (St. Louis, MO, USA);
bupropion, benzydamine and alamethicin from Alfa Aesar
(Ward Hill, MA, USA); oxcarbazepine from European
Pharmacopoeia Reference Standard (Strasbourg, France);
ticlopidine from Tokyo Chemical Industry (Tokyo, Japan);
hydroxybupropion from Cerilliant Corporation (Round
Rock, Texas, USA); deuterated acetone (acetone-d6) from
Cambridge Isotope Labs (Cambridge, MA, USA); hydrogen peroxide (50%) from Univar (Redmond, WA, USA);
HLM, rat liver microsomes (RLM), DLM and human lung
microsomes (HLungM) from Sekisui XenoTech (Kansas
City, KS, USA); human recombinant CYP (rCYP) bactosomes expressed in Escherichia coli (E. coli) from Cypex
(Dundee, Scotland); human recombinant flavin monooxygenase (rFMO) supersomes and human recombinant UGT
(rUGT) supersomes expressed in insect cells from Corning
(Woburn, MA, USA).

TATP, deuterated TATP (TATP‑d18) and hydroxy‑TATP
(TATP‑OH) synthesis
TATP was synthesized following the literature methods
using hydrochloric acid as the catalyst [1]. TATP was purified by recrystallization, first with methanol/water (80:20,
v/v) and then with pentane. TATP-d18 was synthesized as
above using acetone-d6. TATP-OH was synthesized as above
using hydrogen peroxide (50 wt%)/acetone/hydroxyacetone
(2:1:1, v/v/v) [15]. TATP-OH was purified using a CombiFlash RF + system with an attached PurIon S MS system
(Teledyne Isco, Lincoln, NE, USA), followed by two cycles
of drying and reconstituting in solvent to sublime away the
TATP. Separation was performed using a C-18 cartridge
combined with a liquid chromatograph flow of 18 mL/min
with 10% methanol (A) and 90% aqueous 10 mM ammonium acetate (B) for 1 min, before ramping to 35%A/65%B
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over 1 min, followed by another ramp to 95%A/5%B over
the next 1 min, holding for 2 min, before a 30 s transition to
initial conditions, with a hold of 2 min [15].

Instrumental analyses
Metabolite identification was performed by high‐performance liquid chromatography coupled to Thermo Scientific Exactive or Thermo Scientific LTQ Orbitrap XL highresolution mass spectrometers (HPLC–HRMS) (Thermo
Fisher Scientific, Waltham, MA, USA). A CTC Analytics
PAL autosampler (CTC Analytics, Zwingen, Switzerland)
was used for LC injections, solvent delivery was performed
using a Thermo Scientific Accela 1200 quaternary pump,
and data collection/analysis was done using Xcalibur software (Thermo Scientific, version 2.1).
Metabolite quantification was performed by high‐performance liquid chromatography coupled to AB Sciex Q-Trap
5500 triple quadrupole mass spectrometer (HPLC–MS/MS)
(AB Sciex, Toronto, Canada). A CTC Analytics PAL autosampler was used for LC injections, solvent delivery was performed using a Thermo Scientific Accela 1200 quaternary
pump and data collection/analysis was done with Analyst
software (AB Sciex, version 1.6.2).
The HPLC method for all TATP derivatives was as follows: sample of 40 µL (Exactive and LTQ Orbitrap XL)
or 20 µL (Q-Trap 5500) in acetonitrile/water (50:50, v/v)
was injected into LC flow at 250 µL/min of 10%A/90%B
for introduction onto a Thermo Syncronis C18 column
(50 × 2.1 mm i.d., particle size 5 µm). Initial conditions
were held for 1 min before ramping to 35%A/65%B over
1 min, followed by another ramp to 95%A/5%B over the
next 1 min. This ratio was held for 2 min before reverting to
initial conditions over 30 s, which was held for additional
2 min. The Exactive MS tune conditions for atmospheric
pressure chemical ionization (APCI) in positive mode were
as follows: N2 sheath gas flow rate, 30 arbitrary units (AU);
N2 auxiliary gas flow rate, 30 AU; discharge current, 6 µA;
capillary temperature, 220 ℃; capillary voltage, 25 V; tube
lens voltage, 40 V; skimmer voltage, 14 V; and vaporizer
temperature, 220 ℃. The Exactive MS tune conditions for
electrospray ionization (ESI) in negative mode were as follows: N2 sheath gas flow rate, 30 AU; N
 2 auxiliary gas flow
rate, 15 AU; spray voltage, − 3.4 kV; capillary temperature, 275 ℃; capillary voltage, − 35 V; tube lens voltage,
− 150 V; and skimmer voltage, − 22 V. The LTQ Orbitrap
XL MS tune conditions for ESI−, used for TATP-O-glucuronide verification, were as follows: N2 sheath gas flow rate,
30 AU; N
 2 auxiliary gas flow rate, 15 AU; spray voltage,
− 4 kV; capillary temperature, 275 °C; capillary voltage,
− 15 V; and tube lens voltage, − 84 V. The single-reaction
monitoring settings were as follows: m/z 413.13 with isolation width m/z 1.7, activated by higher-energy collision

dissociation at 35 eV. The Q-trap 5500 MS tune and multiple reaction monitoring (MRM) conditions are shown in
Table 1. TATP and TATP-OH quantification was done as the
area ratio to TATP-d18 (internal standard, IS) using a standard curve ranging 10–20,000 ng/mL and 10–500 (Fig. S1) or
500–8,000 ng/mL, respectively. TATP-O-glucuronide relative quantification was done as the area ratio to 2,4-dichlorophenoxyacetic acid (IS).
The HPLC method for bupropion, hydroxybupropion,
benzydamine, benzydamine N-oxide, and oxcarbazepine
(IS) was as follow: sample of 10 μL in acetonitrile/water
(50:50, v/v) was injected into LC flow at 250 μL/min with
30%A/70%B for introduction onto a Thermo Scientific
Acclaim Polar Advantage II C18 column (50 × 2.1 mm i.d.,
particle size 3 µm). Initial conditions were held for 1 min
before instant increase to 95%A/5%B, held for 2.5 min, and
then reversed to initial conditions over 30 s, with a hold of
1 min for the bupropion, hydroxybupropion and oxcarbazepine method or with a hold of 3 min for the benzydamine,
benzydamine N-oxide and oxcarbazepine method.

Metabolite identification
All incubations were performed in triplicate in a Thermo
Scientific Digital Heating Shaking Drybath set to body temperature 37 ℃ and 800 rpm. An incubation mixture containing phosphate buffer (pH 7.4), MgCl2 [17], and NADPH
(CYP cofactor [11]) was prepared so that at a final volume
of 1 mL, their concentrations were 10, 2 and 1 mM, respectively. When the incubation times were relatively long
(greater than 15 min), it was thought necessary to use closed
vessels to avoid loss of the volatile TATP or TATP-OH; as a
result, prior to incubation, oxygen gas was bubbled through
the buffer to ensure ample oxygen availability [15]. To this
mixture, microsomes or recombinant enzymes were added
and equilibrated for 3 min before the reaction was initiated
by adding the substrate. Substrates included TATP in acetonitrile, TATP-OH in methanol, and bupropion and benzydamine in water. Organic solvents can disrupt metabolism,
but the catalytic activity of most CYP enzymes is unaffected
by less than 1% acetonitrile or methanol [18]. At the end
point, an aliquot was transferred to a vial containing equal
volume of ice-cold acetonitrile and immediately vortexmixed to quench the reaction. The sample was centrifuged
for 5 min at 14,000 rpm, and the supernatant was analyzed
by LC–MS.
Metabolite identification studies used microsomes (HLM,
RLM and DLM) at protein concentrations of 1 mg/mL in
the incubation mixture. The substrate, TATP, TATP-OH, or
TATP-d18 (10 µg/mL) was allowed to incubate for several
min before MS analysis. Negative controls consisted of the
incubation mixture excluding either microsomes or NADPH.
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13
− 4500
N/A
50
2
28
6
− 26
− 10
219 → 161, 125
− 13, − 27
− 36, − 20
TATP-O-gluc
413 → 113, 87

TATP-OH
256 → 75
13
36

N/A
0.8

50
2
28
6
26

10
258 → 80, 46

11, 27
14, 20

TATP
240 → 74, 43

11, 28
10, 11

17, 23
20, 10

BUP
240 → 184, 166

27, 39
22, 14

10
253 → 208, 180

20
2
30
5
30

4500
N/A

ESI +
260

Method 3

15, 33
12, 16

BUP-OH
256 → 238, 139

21
10

BZD
310 → 86

19
12

BZD-NO
326 → 102

APCI + positive mode atmospheric pressure chemical ionization, BUP bupropion, BUP-OH hydroxybupropion, BZD benzydamine, BZD-NO benzydamine N-oxide, ESI + positive mode electrospray ionization, ESI- negative mode electrospray ionization, MRM multiple reaction monitoring, N/A not applicable, TATP triacetone triperoxide, TATP-O-gluc triacetone triperoxide-O-glucuronide, TATP-OH hydroxyl-triacetone triperoxide

− 22, − 34
− 13, − 9

ESI −
300

APCI +
300

Source type
Source temperature
(℃)
Ion spray voltage (V)
Nebulizer current
(µA)
Ion source gas 1 (psi)
Ion source gas 2 (psi)
Curtain gas (psi)
Collision gas (psi)
Declustering potential
(V)
Entrance potential (V)
Internal standard
MRM transitions
(m/z)
Collision energy (V)
Collision cell exit
potential (V)
Analyte
Analyte MRM transition (m/z)
Collision energy (V)
Collision cell exit
potential (V)

Method 2

Method 1

Parameter

Table 1  Triple quadrupole mass spectrometer (Q-trap 5500) operating parameters
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Positive control used 100 µM bupropion, a probe substrate
for CYP2B6 [19–21].
Phase II TATP metabolism was examined by two studies.
Metabolism by glutathione S-transferase (GST) was probed
by equilibrating 5 mM GSH (GST cofactor [11]) for 5 min in
the incubation mixture including HLM before the substrate
(TATP) was added. Ticlopidine (10 µM) was the substrate
for the GST positive control (Fig. S2) [22]. To examine
metabolism by UGT, HLM, buffer, and alamethicin (50 µg/
mL in methanol/water) were equilibrated cold for 15 min,
before saccharolactone (1 mg/mL, β-glucuronidase inhibitor
[23]), MgCl2, and NADPH were added, and the mixture was
warmed to 37 ℃ and shaken at 800 rpm. After 3 min equilibration, the substrate (TATP or TATP-OH) was added, and
in 2 min, the reaction was started by the addition of 5.5 mM
UDPGA (UGT cofactor [11]) [24, 25]. Positive control used
100 µM 1-naphthol, an UGT1A6 substrate (Fig. S3) [26, 27].
Alamethicin was employed to replace membrane transporters, in allowing UGT (located in the endoplasmic reticulum
lumen) easy access to the UDPGA cofactor [11].

Enzyme identification
TATP was incubated as described in the previous section
with various enzyme inhibitors in HLM (1 mg/mL). TATPOH formation was first monitored and benchmarked against
incubations without inhibitors. Chemical inhibitors, such
as 1-aminobenzotriazole (1 mM) [28, 29], methimazole
(500 µM) [30, 31], or ticlopidine (100 µM) [32, 33], were
pre-equilibrated in the incubation mixture for 30 min prior
to the addition of the substrate (100 µM, TATP or controls).
TATP was also tested as a possible CYP2B6 inhibitor; TATP
or bupropion was pre-equilibrated in the incubation mixture
before starting the reaction with a known CYP2B6 substrate
(bupropion) or TATP, respectively. FMO inhibition by heat
was also tested [11, 34]. In that experiment, HLM was mixed
with buffer and preheated at 37 or 45 ℃ for 5 min. After an
hour, cooling on ice, the incubation procedure was resumed.
Bupropion, a CYP2B6 substrate [19–21], and benzydamine,
an FMO substrate [34], were used as positive and negative
control substrates to assess CYP, FMO and CYP2B6 inhibition. Samples not preincubated with chemical inhibitors nor
heated to 45 ℃ were used as 100% TATP-OH formation.
Inhibition studies were quenched after 15 min incubation.
Recombinant CYP and FMO enzymes were employed to
identify the isoform responsible for the NADPH-dependent
metabolism. Human bactosomes expressed in E. coli were
used for CYP isoform identification; CYP1A2, CYP2B6,
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4
(100 pmol CYP/mL) were tested. Human supersomes
expressed in insect cells were used for FMO isoform identification; FMO1, FMO3 and FMO5 (100 µg protein/mL)
were examined. Both TATP and TATP-OH were tested as

the substrate (10 µg/mL) in the incubation mixture with the
recombinant enzymes. Negative control incubations were
done in E. coli control or insect cell control. Positive control
incubations were done in HLM (200 pmol CYP/mL), which
contains all CYP and FMO enzymes. Recombinant enzymes
studies were quenched after 10 min incubation.
Recombinant UGT enzymes were used to identify the
isoform responsible for phase II metabolism. Human supersomes expressed in insect cells were used for UGT isoform
identification; UGT1A1, UGT1A3, UGT1A4, UGT1A6,
UGT1A9 and UGT2B7 were examined. The incubation
mixture was similar to the glucuronidation incubation previously described, except that saccharolactone was not added
[35]; 500 µg protein/mL was used; and the substrate was
10 µg/mL TATP-OH. Negative control incubations were
done in insect cell control. Positive control incubations were
done in HLM (1 mg protein/mL), which contained all UGT
enzymes. Glucuronidation with recombinant enzymes was
quenched after 2 h incubation.

Enzyme kinetics
Kinetics experiments were done to determine the affinity
of the enzyme CYP2B6 to the substrate TATP. The human
CYP2B6 bactosomes used contained human CYP2B6 and
human CYP reductase coexpressed in E. coli, supplemented
with purified human cytochrome b5. Cytochrome P450
reductase is responsible for the transfer of electrons from
NADPH to CYP, a task sometimes extended to cytochrome
b5 [11]. The incubation mixture (1 mL) contained 10 mM
phosphate buffer (pH 7.4), 2 mM MgCl2, 50 nM rCYP2B6,
1 mM NADPH, and various concentrations of 0.1 to 20 µM
TATP. The reaction was initiated by adding TATP after a
3 min pre-equilibration and stopped at different end points
(up to 5 min) to determine rate of TATP hydroxylation. The
rate of TATP hydroxylation in lungs was also investigated by
incubating TATP (100 µM) in the incubation mixture containing 1 mg/mL HLM or HLungM, instead of rCYP2B6,
for up to 10 min.
TATP-OH metabolism by CYP2B6 was evaluated by
incubating 10 µg/mL TATP-OH in CYP2B6 bactosomes
according to the above procedure, with or without NADPH,
except that the buffer was preoxygenated so that the incubation could be performed in a closed vessel. Aliquots
were removed and quenched at different time points, up to
30 min. TATP-OH depletion by HLM was determined using
the same procedure, except that 1 µM TATP-OH and up to
60 min reaction times were used.

Urine analysis
Laboratory personnel testing TATP are constantly exposed
to this volatile compound. Explosive sensitivity experiments,
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Fig. 1  Triacetone triperoxide
(TATP) biotransformation into
hydroxy-TATP (TATP-OH)
monitored over time in human
liver microsomes (HLM), performed in triplicate

Fig. 2  TATP metabolic pathways in HLM. CYP cytochrome P450, UGTuridine diphosphoglucuronosyltransferase

such as drop weight impact tests, are done in a small brickwalled room for explosivity precautions, unlike synthesis
reactions which are performed inside a fume hood for coverage protection. Also, portable explosive trace detection
devices that are meant to be used in the field are tested as
such, which also contribute to exposure. Urine from laboratory workers was tested for TATP and its metabolites after
TATP exposure in the laboratory environment. Urine was
collected at the beginning of the work week and 2 h after
performing activities that could lead to high TATP exposure.
To determine the longevity of TATP in the body, urine from
the day following TATP exposure was also tested. The fresh
urine was cleaned and concentrated for analysis using solidphase extraction. Restek RDX column (Restek, Bellefonte,
PA, USA) was conditioned with 6 mL of methanol, followed
by 6 mL of water, and sample introduction (20–250 mL
urine). The sample was washed with two cycles of 3 mL
methanol/water (50:50, v/v). Extraction was achieved with
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two cycles of 1 mL acetonitrile. Both eluents were tested by
LC–MS, because the lipophilic TATP and TATP-OH were
extracted with acetonitrile, but the hydrophilic TATP-O-glucuronide was present in the methanol/water wash.

Results
Metabolite identification
When TATP was incubated in HLM, TATP was depleted,
and one observable product, TATP-OH, was formed over
time (Fig. 1). Metabolism of TATP in HLM consists of
hydroxylation at one methyl group with the peroxide bonds
and nine-membered ring structure preserved (Fig. 2) [15].
Opsenica and Solaja [12] reported various monohydroxylated and dihydroxylated products during microsomal
incubations with cyclohexylidene and steroidal mixed
tetraoxanes where the peroxide bond was also preserved. A

Forensic Toxicology

Fig. 3  Product ion spectrum of [TATP-O-glucuronide − H]− (m/z 413.1301), fragmented with 35 eV using electrospray ionization in negative
mode (ESI–). Proposed structures are shown

TATP-OH standard (Fig. S4) was chemically synthesized to
confirm the metabolite by retention time and mass-to-charge
ratio (m/z). TATP-OH, identified as [TATP-OH + NH4]+ (m/z
256.1391) by accurate mass spectrometry, increased in incubation samples as time progressed. Attempts to confirm the
hydroxylated metabolite with the deuterated substrate were
unsuccessful due to the persistence of a contaminant with
the same mass that the metabolite would have had, even in
samples where TATP-d18 was not used as the substrate. As
previously observed, TATP incubations in different species
(dogs and rats) yielded the same metabolite, TATP-OH (Fig.
S5) [15]. Other suspected metabolites, including the dihydroxy-species and additional oxidation of the TATP-OH to
Table 2  Average % metabolites
formed (triplicates) in 15 min
incubations with chemical
inhibitors or heat

the aldehyde and carboxylic acid were not observed. Small
polar molecules, such as acetone and hydrogen peroxide, the
synthetic reagents of TATP, could not be chromatographically separated or are below the lower mass filter limit.
TATP was investigated for phase II metabolism routes
of glutathione and glucuronide conjugation. Incubation
in HLM with GSH produced no detectable glutathione
metabolite conjugates, indicating that TATP is most
likely not a substrate for microsomal GSTs (Fig. S6).
When TATP was incubated with UDPGA, the TATP-OH
glucuronic acid metabolite (TATP-O-glucuronide) was
observed (Fig. 2). The m/z 432.1712 for [TATP-O-glucuronide + NH4]+ was observed at very low levels after

Metabolite forPercent found
mation in 15 min
Inhibitor preincubated in HLM for 30 min

TATP-OH (%)
BUP-OH (%)
BZD-NO (%)

HLM preheated
for 5 min

No inhibitor

1-ABT

MMI

TIC

TATP or BUP

37 ℃

45 ℃

100 ± 5
100 ± 3
100 ± 2

3.6 ± 0.7
23 ± 1
97 ± 1

34 ± 2
62 ± 2
48 ± 1

4.8 ± 0.7
9.6 ± 0.4
98 ± 3

125 ± 21
62 ± 2
N/A

100 ± 10
100 ± 6
100 ± 2

69 ± 4
99 ± 2
44 ± 2

1-ABT 1-aminobenzotriazole (CYP inhibitor), CYP cytochrome P450, FMO flavin monooxygenase, HLM
human liver microsomes, MMI methimazole (FMO inhibitor), TIC ticlopidine (CYP2B6 inhibitor) (for
other abbreviations, see Table 1)
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Table 3  Average % TATP-OH remaining (triplicates) after 10 min
incubation in recombinant enzymes

Fig. 4  TATP-OH formation from TATP incubations with recombinant cytochrome P450 (rCYP) and recombinant flavin monooxygenase (rFMO). Experiments with rCYP or rFMO consisted of 10 µg/
mL TATP incubated with 10 mM phosphate buffer (pH 7.4), 2 mM
MgCl2 and 1 mM NADPH. Incubations were done in triplicate and
quenched at 10 min

2 and 3 h of incubation. When the sample was dried and
reconstituted in low volume, the intensity of [TATPO-glucuronide + NH4]+ increased, but TATP and TATPOH were evaporated along with the solvent. TATP and
TATP-OH are volatile, limiting their use in quantification
experiments since sample concentration is not feasible [5].
However, TATP-O-glucuronide is a non-volatile TATP
derivative that is amenable to sample preparation. Formation of TATP-O-glucuronide over time was monitored,
using concentrated samples, as an intensity increase of
m/z 432.1712 (Fig. S7). Even though TATP and TATPOH generally form ammonia adducts under positive ion
APCI, the glucuronide favors negative ion mode ESI. The
m/z 413.1301 for [TATP-O-glucuronide − H]− was easily
seen at 1–3 h without sample concentration. The common
fragments of glucuronic acid, m/z 175, 113, and 85, were
observed in the fragmentation pattern of m/z 413.1301,
confirming the presence of a glucuronic acid conjugate
(Fig. 3) [36]. TATP-O-glucuronide was not observed in
negative controls without UDPGA or NADPH, indicating
that TATP-OH must be formed and then be further metabolized into TATP-O-glucuronide. Glucuronide conjugates
are highly polar compounds that are easily eliminated by
the kidney, suggesting that TATP-O-glucuronide would
likely progress via urinary excretion [11].

Enzyme identification
TATP was only metabolized into TATP-OH in HLM in
the presence of NADPH, indicating that the metabolism is
NADPH-dependent. The predominant microsomal enzymes
that require NADPH for activity are CYP and FMO [11].
The usual roles of CYP are hydroxylation of an aliphatic or aromatic carbons, epoxidation of double bonds,
heteroatom oxygenation or dealkylation, oxidative group
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Incubation matrix

Percent TATPOH remaining

HLM
rCYP control
rCYP1A2
rCYP2B6
rCYP2C9
rCYP2C19
rCYP2D6
rCYP2E1
rCYP3A4
rFMO control
rFMO1
rFMO3
rFMO5

69 ± 5
76 ± 4
77 ± 2
60 ± 3
71 ± 8
76 ± 5
76 ± 5
73 ± 5
78 ± 6
69 ± 3
78 ± 12
78 ± 6
72 ± 7

rCYP recombinant cytochrome P450, rFMO recombinant flavin
monooxygenase

transfer, cleavage of esters and dehydrogenation reactions
[11]. 1-Aminobenzotriazole is considered a general mechanism-based inhibitor of CYPs, initiated by metabolism into
benzyne, which irreversibly reacts with the CYP heme [28,
29]. When CYP activity was inhibited by 1-aminobenzotriazole, TATP-OH formation was also inhibited, with only
3.6% formed (Table 2), suggesting that CYP is involved in
the hydroxylation of TATP. To support this evidence and to
narrow down the CYP isoform catalyzing TATP hydroxylation, TATP was incubated with rCYPs (Fig. 4, Table S1).
The CYPs selected for testing are responsible for the metabolism of 89% of common xenobiotics [37]. TATP-OH was
not observed when TATP was incubated with CYP1A2,
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.
TATP hydroxylation was performed exclusively by CYP2B6,
with 5.6 ± 0.3 µM TATP-OH produced in 10 min. CYP2B6
has been found to metabolize endoperoxides by hydroxylation, as observed for TATP [13, 14]. HLM, which contains
CYP2B6, also exhibited TATP hydroxylation (1.5 ± 0.1 µM).
Since DLM studies indicated that TATP is metabolized
by CYP2B11 [15], it was not surprising that another CYP2B
subfamily enzyme, CYP2B6, metabolizes TATP in humans.
CYP2B6 metabolism of TATP was further investigated by
incubating TATP with ticlopidine, a mechanism-based
inhibitor of CYP2B6 [32, 33]. When CYP2B6 activity
was inhibited by ticlopidine, TATP-OH formation was also
inhibited by 95% (Table 2), further supporting the primary
involvement of CYP2B6 in the metabolism of TATP. Bupropion hydroxylation is catalyzed by CYP2B6; therefore, it
was chosen as a positive control for CYP and CYP2B6 inhibition tests [28]. Hydroxybupropion formation was inhibited
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Fig. 5  TATP-O-glucuronide formation from TATP-OH incubations
with recombinant uridine diphosphoglucuronosyltransferase (rUGT).
Experiments with rUGT consisted of 10 µg/mL TATP-OH incubated with 10 mM phosphate buffer (pH 7.4), 2 mM MgCl2, 50 µg/
mL alamethicin, 1 mM NADPH, and 5.5 mM uridine diphosphoglucuronic acid. Glucuronidation done in triplicate and quenched at 2 h.
Quantification was done using area ratio TATP-O-glucuronide/internal standard 2,4-dichlorophenoxyacetic acid

by 77 and 90% when incubated with 1-aminobenzotriazole
and ticlopidine, respectively (Table 2).
FMO catalyzes oxygenation of nucleophilic heteroatoms,
such as nitrogen, sulfur, phosphorous and selenium [34,
38]. Although FMO involvement in the hydroxylation of
the TATP methyl group was unlikely, it seemed prudent to
examine this enzyme class. Addition of methimazole, an
FMO competitive inhibitor [30, 31], caused a decrease in
TATP-OH formation by 66% (Table 2), but this is not necessarily direct inhibition of TATP metabolism by FMO since
methimazole has been reported to reduce CYP2B6 activity
by up to 80% [34, 39]. While this result was inconclusive
about the FMO contributions to TATP metabolism, it could
be considered further support for the role of CYP2B6. TATP
was incubated with available rFMOs: FMO1, FMO3 and

Fig. 6  Rate of TATP hydroxylation by CYP2B6 versus TATP concentration. Incubations of various TATP concentrations consisted of
50 pmol rCYP2B6/mL with 10 mM phosphate buffer (pH 7.4), 2 mM
MgCl2 and 1 mM NADPH. Incubations were done in triplicate and
quenched every min up to 5 min

FMO5 (Fig. 4, Table S1). FMO1 is expressed in adults in the
kidneys, and it should not contribute to the liver metabolism
of TATP [34]; indeed, none appeared to be involved as no
TATP-OH was produced (positive control, Fig. S8). Since
FMO is inactivated by heat [11, 34], TATP was incubated
in HLM pre-heated to 45 ℃ for 5 min. Table 2 compares the
formation of TATP-OH at 37 ℃ to that at 45 ℃ and to the
N-oxidation of the positive control, benzydamine. Although,
there was a decrease in TATP hydroxylation, the inhibitory
effect was not as significant as compared to the decrease in
benzydamine N-oxidation, which is catalyzed by FMO.
TATP-OH appears to be metabolized by HLM in an
NADPH-dependent manner; therefore, TATP-OH was
incubated for 10 min with recombinant enzymes (CYP and
FMO) to determine which isoform is responsible for this
secondary phase I metabolism (Table 3). Although TATPOH is not nearly as volatile as TATP, some TATP-OH was
lost in all incubations (i.e., 37 ℃); however, notable depletion (by 40%) was observed only with CYP2B6. TATP-OH
depletion in CYP2B6 was faster in the presence of NADPH
than in its absence, supporting metabolism by CYP2B6 (Fig.
S9). Unfortunately, no subsequent metabolite was identified.
To identify which isoform is responsible for TATP glucuronidation, TATP-OH was incubated with the most clinically
relevant rUGTs (Fig. 5, Table S2) [40]. Glucuronidation was
not observed with UGT1A1, UGT1A3, UGT1A4, UGT1A6
and UGT1A9. TATP-O-glucuronide was formed only in
UGT2B7 incubations with 0.05 ± 0.03 area count relative
to IS produced after 2 h of incubation. HLM, which contains
UGT2B7, also displayed TATP-O-glucuronide (0.26 ± 0.02
area count relative to IS). Relative quantification of TATPO-glucuronide was done by area ratio to the IS because a
TATP-O-glucuronide standard is not available. Endoperoxide glucuronidation by UGT2B7 has been reported, in
which urine analysis of patients treated with artesunate, an

Fig. 7  Natural log of TATP-OH percent remaining in HLM versus
time. TATP-OH (1 µM) incubated in 1 mg/mL HLM with preoxygenated 10 mM phosphate buffer (pH 7.4), 2 mM MgCl2 and 1 mM
NADPH. Incubations were done in closed vials, in triplicate and
quenched every 10 min up to 1 h
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artemisinin derivative, found dihydroartemisinin-glucuronide to be the principal metabolite excreted [16].

Enzyme kinetics
Rate of TATP hydroxylation by CYP2B6 was evaluated by
plotting concentration of TATP-OH formed over time. The
initial rate of TATP hydroxylation at various TATP concentrations was used to estimate enzyme kinetics
( using the
)
Michaelis–Menten model: v = Vmax × [S]∕ Km + [S] .
Here, [S] is the substrate (TATP) concentration, Vmax is
the maximum formation rate, Km is the substrate concentration at half of Vmax, and kcat is the turnover rate of an
enzyme–substrate complex to product and enzyme [41]. The
kinetic constants were obtained using nonlinear regression
analysis on GraphPad Prism software (version 8.2.1). The
Michaelis–Menten evaluation for TATP hydroxylation by
CYP2B6 (Fig. 6) yielded Km of 1.4 µM; Vmax of 8.7 nmol/
min/nmol CYP2B6; and kcat of 174 min− 1. Linearized models, such as Lineweaver–Burk (Fig. S10), Eadie–Hofstee
(Fig. S11) and Hanes–Woolf (Fig. S12), give similar values.
The low K m indicates TATP has a high affinity for
CYP2B6 [42]. Table 2 shows that TATP inhibits bupropion hydroxylation by CYP2B6, with only 62% hydroxybupropion formation in 15 min. However, in the presence of
bupropion, TATP-OH formation was enhanced, with 125%
formed compared to the reaction uninhibited by bupropion
(Table 2). CYP2B6 preference for TATP affects the metabolism of bupropion, but further testing is needed to establish
the specific type of inhibition.
Using the Michaelis–Menten parameters, in vitro intrinsic
clearance (Clint = Vmax ∕Km ) was calculated to be 6.13 mL/
min/nmol CYP2B6 [11, 43, 44]. Scale-up of the Clint to yield
intrinsic clearance on a per kilogram body weight was done
using values of 0.088 nmol CYP2B6/mg microsomal protein, 45 mg microsomal protein/g liver wet weight and 20 g
liver wet weight/kg human body weight [43]. Taking that
into account, the scale-up Clint was calculated to be 485 mL/
min/kg.
In vivo intrinsic clearance (Cl) is the ability of the
liver to metabolize and remove a xenobiotic, assuming
normal hepatic blood flow (Q = 21 mL/min/kg [43, 45])
and no protein binding [43]. Cl can be extrapolated using
Table 4  Rate of TATP hydroxylation (triplicates) in human liver
microsomes versus human lung microsomes
Human microsomes

Rate of TATP-OH
formation (nmol/min/
mg)

Liver
Lung lot1710142
Lung lot1410246

0.425 ± 0.06
< LOQ
< LOQ

< LOQ lower than the limit of quantification
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the well-stirred model excluding all protein binding as
Cl = Q × Clint ∕Q + Clint [43]. The in vivo intrinsic clearance of TATP was estimated as 20 mL/min/kg. Compared to
common drugs, TATP has a moderate clearance [46].
TATP-OH kinetics were also investigated by substrate
depletion. Substrate depletion was plotted as the natural
log of substrate percent remaining over time (Fig. 7). Halflife (t1/2) was calculated to be 16 min, as the natural log
2 divided by the negative slope of the substrate depletion
plot. In vitro intrinsic clearance (Clint) can also be estimated
using half-life as Clint = (0.693/t1/2) × (incubation volume/mg
microsomal protein) [47, 48]. The in vitro intrinsic clearance of TATP-OH was estimated as 0.042 mL/min/mg. Even
though we identified two metabolic pathways for TATP-OH,
it appears to be cleared slower than TATP.

Lung metabolism
Inhalation is the most probable pathway for systemic exposure since TATP is both volatile and lipophilic. With passive
diffusion into the bloodstream being very possible, TATP
metabolism in the lung was also investigated. TATP was
incubated in lung and liver microsomes for comparison of
metabolic rate. The results, shown in Table 4, indicated that
TATP hydroxylation in the lungs was negligible. Though
CYP2B6 gene and protein are expressed in the lungs,
enzyme activity in lungs is minimal as compared to the liver,
limiting TATP metabolism [49, 50]. This suggests that TATP
is most likely distributed through the blood to the liver for
metabolism. News reported that traces of TATP was found in
the blood samples extracted from the 2016 Brussels suicide
bombers [51]. This indicates the possibility of using blood
tests as forensic evidence for TATP exposure.

In vivo human urine analysis
Laboratory workers, who normally work with TATP on a
daily basis, performing tasks like explosive sensitivity testing, were screened for TATP exposure. These laboratory
workers volunteered to collect their urine before and after
exposure to TATP vapor. Since the health effects of TATP
exposure are unknown, to minimize any additional risks to
these workers, this pilot study was performed in duplicates
using only three volunteers to establish some reproducibility. TATP and TATP-OH were not observed in the urine of
any of the workers. However, TATP-O-glucuronide was present in all urine samples collected 2 h after TATP exposure
(Fig. 8). Two out of the three volunteers still showed TATPO-glucuronide in the urine collected the next day (Table 5).
TATP-O-glucuronide was identified in human urine samples
as both [TATP-O-glucuronide − H]− and [TATP-O-glucuronide + NH4]+. The presence of TATP-O-glucuronide in the
urine of all three volunteers is summarized in Table 5.
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Fig. 8  Extracted ion chromatogram of [TATP-O-glucuronide − H]− (m/z 413.1301) in HLM 2 h after incubation with TATP, and in human
urine, before TATP exposure and 2 h after TATP exposure
Table 5  Summary of TATP-Oglucuronide presence in human
urine (duplicates) in vivo

Human

Before TATP exposure
Two hours after TATP exposure
One day after TATP exposure

m/z 413.1301

m/z 432.1712

#1

#2

#3

#1

#2

#3

−
+
+

−
+
+

−
+
−

−
+
+

−
+
−

−
+
−

TATP glucuronide is observed as [TATP-O-glucuronide − H]− (m/z 413.1301) and [TATP-O-glucuronide + NH4]+ (m/z 432.1712, less sensitive). Only one trial performed on next day samples

Discussion
As described before, TATP is the explosive of choice by
terrorists because it is easily synthesized from household
items [1, 2]. In our previous study, we have clarified that
TATP-OH is produced as an in vitro metabolite from TATP
in dogs [15], because canines are currently one of the most
reliable detection techniques used to find an explosive
[52]. In the present article, the study has been conducted
in continuation of our previous findings on both in vitro
and in vivo metabolism of TATP in humans (Fig. 2).
Because TATP has high volatility, it is likely to be
absorbed into the body by inhalation; however, no

appreciable metabolism in the lung was observed in either
dog [15] or human microsomes (Table 4). Therefore, systemic exposure and subsequent liver metabolic clearance
were presumed. Across three species, dog, rat, and human,
TATP was metabolized in liver microsomes by CYP to
TATP-OH (Fig. S5). Using recombinant enzymes, we
have previously established that CYP2B11 is responsible
for this metabolism in dogs [15]. Interestingly, human
CYP2B6 appears to be the major phase I enzyme responsible for the same metabolism (Fig. 4). TATP hydroxylation by CYP2B6 kinetics determined K m and V max as
1.4 µM and 8.7 nmol/min/nmol CYP2B6, respectively
(Fig. 6). Though heat inactivation and chemical inhibition
of FMO appeared to affect TATP hydroxylation (Table 2),
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incubations with recombinant FMO suggest that FMO was
not forming TATP-OH (Fig. 4). Methimazole, an FMO
inhibitor, inhibited TATP-OH formation (Table 2); but,
inhibition of bupropion by this chemical inhibitor suggests
that methimazole also inhibits CYP2B6 activity [39].
When incubated together, TATP and bupropion appear to
compete for CYP2B6 metabolism, with bupropion hydroxylation being inhibited by 38% in the presence of TATP
(Table 2). Considering CYP2B6 expression in the liver is
low and exhibits broad genetic polymorphisms, CYP2B6
activity can be widely affected if TATP affects the metabolism of other compounds, like bupropion [53, 54]. TATP
may be a serious perpetrator for drug-drug interactions for
compounds cleared by CYP2B6 [55, 56].
In vitro clearance of TATP was calculated as 0.54 mL/
min/mg protein with hepatic in vivo extrapolation to
20 mL/min/kg. In vitro clearance of TATP-OH was estimated, using substrate depletion, as 0.038 mL/min/mg protein (Fig. 7). We also established the clearance of TATP
in dogs as 0.36 mL/min/mg protein in our previous study
in canine microsomes [15], which is significantly relevant
to K9 units, where the dog and human handler are both
exposed to the explosive.
Investigation into the next step on the metabolic pathway suggested that TATP-OH is further metabolized by
CYP2B6 (Table 3), but a secondary phase I metabolite
was not identified. No glutathione adducts of any TATP
metabolism products were observed in the microsomal
incubations with GSH (Fig. S6). However, glucuronidation converted TATP-OH to TATP-O-glucuronide in
HLM with UGT2B7 specifically catalyzing this reaction
(Fig. 5). Considering glucuronides are often observed as
urinary metabolites, the presence of TATP-O-glucuronide
in urine can be exploited as an absolute marker of exposure to TATP, which can be used as forensic evidence of
TATP illegal use.
Urine from scientists working to prevent terrorist attacks
by synthesizing, characterizing and detecting TATP, who
are inevitably exposed to this volatile compound were negatively tested for TATP and TATP-OH, but TATP-O-glucuronide was present at high levels in their fresh urine (Fig. 8).
In one out of the three volunteers, TATP-O-glucuronide was
not observed in the urine collected the day after TATP exposure (Table 5), suggesting TATP to TATP-O-glucuronide
in vivo clearance occurs within about a day depending on the
exposure level. TATP-O-glucuronide presence in the urine
of all three volunteers shows good in vivo correlation to
in vitro data.
Like TATP (hydrophilicity expressed as TPSA = 55.38
and lipophilicity expressed as cLogP = 3.01, calculated using
PerkinElmer ChemDraw Professional version 16.0.1.4),
TATP-OH is lipophilic with TPSA and cLogP of 75.61 and
1.72, respectively. TATP-O-glucuronide, on the other hand,
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is hydrophilic with TPSA and cLogP of 171.83 and 0.32,
respectively. The increase in TPSA and decrease in cLogP
from TATP to TATP-O-glucuronide accounts for the glucuronide greater water solubility and facilitated excretion [11],
thus explaining the presence of only TATP-O-glucuronide
in urine.
Even though working with TATP falls under the protection of several standard operating procedures to handling
explosives, considering the breathing exposure that these
laboratory workers revealed, implementation of precautionary measures to absorption by inhalation, such as the use of
respirators, should be considered. Such detection of TATPO-glucuronide is also useful for judicial authorities to raise
a scientific evidence for exposure to TATP of terrorists and/
or related individuals.
This paper is the first to examine some aspects of TATP
human ADMET, elucidating the exposure, metabolism and
excretion of TATP in humans. However, the detailed pharmacological and toxicological studies remain to be explored.

Conclusions
This article dealt with in vitro and in vivo studies of TATP
metabolism in humans. TATP is highly volatile and easily
introduced into human body via aspiration. By this study,
TATP was found to be metabolized into TATP-OH by the
action of CYP2B6, followed by glucuronidation of TATPOH catalyzed by UGT2B7; the resulting TATP-O-glucuronide was found to be excreted into urine in live humans.
After extracting the TATP conjugate from urine specimens,
it can be analyzed by HPLC–MS/MS, which gives scientific evidence for exposure to TATP. This evidence can be
useful to prove exposure of persons, such as terrorists, to
TATP for judicial authorities. Although this study includes
the metabolism of TATP and also an analytical method to
detect the TATP-O-glucuronide, the toxicology of TATP
remains to be explored.
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